ReviewTherapeutic advances in endocrinology and metabolism2022

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.

Bernt Johan von Scholten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.